UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032867
Receipt number R000014893
Scientific Title Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patients
Date of disclosure of the study information 2018/06/05
Last modified on 2018/06/05 00:05:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patients

Acronym

Efficacy of sucroferric oxyhydroxide on HD

Scientific Title

Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patients

Scientific Title:Acronym

Efficacy of sucroferric oxyhydroxide on HD

Region

Japan


Condition

Condition

Chronic kidney disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To observe the efficay nad safetey of sucroferric oxyhydroxide on hemodialysis patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

FGF23 levels and anemia-related parameters

Key secondary outcomes

Ca, P, intact-PTH levels
safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Sucroferric oxyhydroxide

Interventions/Control_2

Lanthanum carbohydrate

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) age > 19 years and < 86 years, (2) hemodialysis duration >6 months at enrollment, and (3) hyperphosphatemia that was treated with lanthanum carbonate at least 12 weeks before enrollment.

Key exclusion criteria

(1) age < 20 years or > 85 years; (2) history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (3) presence of infectious disease, malignant tumors, or treatment with steroids or immunosuppressants; (4) current hospitalization; and (5) treatment with ferric citrate hydrate within the past 6 months.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masanori Abe

Organization

Nihon University School of Medicine

Division name

Nephrology, Hypertension and Endocrinology

Zip code


Address

30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo, Japan

TEL

03-3972-8111

Email

abe.masanori@nihon-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomoyasu Otsuki

Organization

Nihon University School of Medicine

Division name

Nephrology, Hypertension and Endocrinology

Zip code


Address

30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo, Japan

TEL

03-3972-8111

Homepage URL


Email

totsuki16@gmail.com


Sponsor or person

Institute

Department of Nephrology, hypertension and Endocrinology, Nihon University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 06 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 08 Month 31 Day

Date of IRB


Anticipated trial start date

2016 Year 01 Month 06 Day

Last follow-up date

2017 Year 12 Month 31 Day

Date of closure to data entry

2017 Year 12 Month 31 Day

Date trial data considered complete

2017 Year 12 Month 31 Day

Date analysis concluded

2018 Year 03 Month 14 Day


Other

Other related information



Management information

Registered date

2018 Year 06 Month 05 Day

Last modified on

2018 Year 06 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014893


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name